摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(Chloromethyl)-2-(trifluoromethyl)quinoline | 1103795-79-4

中文名称
——
中文别名
——
英文名称
4-(Chloromethyl)-2-(trifluoromethyl)quinoline
英文别名
——
4-(Chloromethyl)-2-(trifluoromethyl)quinoline化学式
CAS
1103795-79-4
化学式
C11H7ClF3N
mdl
——
分子量
245.631
InChiKey
QHSAKEZABUSMAQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors
    摘要:
    We have discovered nanomolar inhibitors of TNF-alpha convertase (TACE) comprised of a novel spirocyclic scaffold and either a carboxylate or hydroxamate zinc binding moiety. X-ray crystal structures and computer models of selected compounds binding to TACE explain the observed SAR. We report the first TACE X-ray crystal structure for an inhibitor with a carboxylate zinc ligand.
    DOI:
    10.1016/j.bmcl.2008.11.034
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF
    申请人:BAYER AKTIENGESELLSCHAFT
    公开号:US20190160048A1
    公开(公告)日:2019-05-30
    The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    该申请涉及新颖的取代5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡啶-3(2H)-酮和2,5,6,7-四氢-3H-吡咯[2,1-c][1,2,4]三唑-3-酮,其制备方法,以及其单独或组合使用用于治疗和/或预防疾病,以及其用于生产用于治疗和/或预防疾病的药物,特别是用于治疗和/或预防肺部炎症性疾病。
  • Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof
    申请人:BAYER AKTIENGESELLSCHAFT
    公开号:US10722501B2
    公开(公告)日:2020-07-28
    The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    本申请涉及式(I)的新型取代的 5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡啶-3(2H)-酮和 2,5,6,7-四氢-3H-吡咯并[2,1-c][1,2,4]三唑-3-酮、其制备工艺、其用途、单独或组合使用,用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防肺部炎症疾病。
  • SUBSTITUIERTE 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE UND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONE UND IHRE VERWENDUNG
    申请人:Bayer Aktiengesellschaft
    公开号:EP3455224A1
    公开(公告)日:2019-03-20
  • [DE] SUBSTITUIERTE 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE UND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONE UND IHRE VERWENDUNG<br/>[EN] SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF<br/>[FR] 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3- A]PYRIDIN-3(2H)-ONES ET 2,5,6,7-TÉTRAHYDRO-3H-PYRROLO[2,1 -C][1,2,4]TRIAZOL-3-ONES SUBSTITUÉES ET LEUR UTILISATION
    申请人:BAYER AG
    公开号:WO2017194459A1
    公开(公告)日:2017-11-16
    Die vorliegende Anmeldung betrifft neue substituierte 5,6,7,8-Tetrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2H)-one und 2,5,6,7-tetrahydro-3H-pyrrolo[2,1 -c][1,2,4]triazol-3-one, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere zur Behandlung und/oder Prophylaxe von inflammatorischen Lungen-Erkrankungen
查看更多